Beta-blocker bashing and downgrading in hypertension management: a fashionable trend representing a matter of concern
J Hypertens
.
2024 Jun 1;42(6):966-967.
doi: 10.1097/HJH.0000000000003735.
Epub 2024 May 1.
Authors
Reinhold Kreutz
1
,
Mattias Brunström
2
,
Michel Burnier
3
,
Guido Grassi
4
,
Andrzej Januszewicz
5
,
Sverre E Kjeldsen
6
7
,
Maria L Muiesan
8
,
Costas Thomopoulos
9
,
Konstantinos Tsioufis
10
,
Giuseppe Mancia
11
Affiliations
1
Charite-Universitätsmedizin Berlin, Institute of Clinical Pharmacology and Toxicology, Germany.
2
Department of Public Health and Clinical Medicine, Umea University, Sweden.
3
Faculty of Biology and Medicine, University of Lausanne, Switzerland.
4
Clinica Medica, University Milano-Bicocca, Milan, Italy.
5
Department of Hypertension, National Institute of Cardiology, Warsaw, Poland.
6
Institute for Clinical Medicine, University of Oslo.
7
Departments of Cardiology and Nephrology, Ullevaal Hospital, Oslo, Norway.
8
OC 2 Medicina, ASST Spedali Civili di Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Italy.
9
Department of Cardiology, General Hospital of Athens "Laiko".
10
First Department of Cardiology, Medical School, University of Athens, Hippokration Hospital, Athens, Greece.
11
University Milano-Bicocca, Italy.
PMID:
38690902
DOI:
10.1097/HJH.0000000000003735
No abstract available
Publication types
Editorial
MeSH terms
Adrenergic beta-Antagonists* / therapeutic use
Antihypertensive Agents / therapeutic use
Humans
Hypertension* / drug therapy
Substances
Adrenergic beta-Antagonists
Antihypertensive Agents